Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer

Key facts

Sponsor

Peking Union Medical College Hospital

Intervention

Camrelizumab(drug)

Enrollment

18 enrolled

Eligibility

18-75 years · All sexes

Timeline

2024 – 2030

Study locations (2)

• Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
• Peking Union Medical College Hospital, Beijing, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Constitutional mismatch repair deficiency syndrome

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT07523763
  Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer
  Blokhin's Russian Cancer Research Center
• RECRUITINGNCT07450612
  Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection
  San Raffaele University
• RECRUITINGPHASE2NCT05729646
  Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
  Yu jiren
• ACTIVE NOT RECRUITINGPHASE2NCT02983578
  Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE1NCT02359565
  Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
  National Cancer Institute (NCI)

See all trials for Constitutional mismatch repair deficiency syndrome →